Cargando…

Hepatic Glucose Output Inhibition by Mexican Plants Used in the Treatment of Type 2 Diabetes

De novo hepatic glucose production or hepatic gluconeogenesis is the main contributor to hyperglycemia in the fasting state in patients with type 2 diabetes (T2D) owing to insulin resistance, which leads to at least twice as much glucose synthesis compared to healthy subjects. Therefore, control of...

Descripción completa

Detalles Bibliográficos
Autores principales: Mata-Torres, Gerardo, Andrade-Cetto, Adolfo, Espinoza-Hernández, Fernanda Artemisa, Cárdenas-Vázquez, René
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7065531/
https://www.ncbi.nlm.nih.gov/pubmed/32194426
http://dx.doi.org/10.3389/fphar.2020.00215
_version_ 1783505076157939712
author Mata-Torres, Gerardo
Andrade-Cetto, Adolfo
Espinoza-Hernández, Fernanda Artemisa
Cárdenas-Vázquez, René
author_facet Mata-Torres, Gerardo
Andrade-Cetto, Adolfo
Espinoza-Hernández, Fernanda Artemisa
Cárdenas-Vázquez, René
author_sort Mata-Torres, Gerardo
collection PubMed
description De novo hepatic glucose production or hepatic gluconeogenesis is the main contributor to hyperglycemia in the fasting state in patients with type 2 diabetes (T2D) owing to insulin resistance, which leads to at least twice as much glucose synthesis compared to healthy subjects. Therefore, control of this pathway is a promising target to avoid the chronic complications associated with elevated glucose levels. Patients with T2D in the rural communities of Mexico use medicinal plants prepared as infusions that are consumed over the day between meals, thus following this rationale (consumption of the infusions in the fasting state), one approach to understanding the possible mechanism of action of medicinal plants is to assess their capacity to inhibit hepatic glucose production. Furthermore, in several of these plants, the presence of phenolic acids able to block the enzyme glucose-6-phosphatase (G6Pase) is reported. In the present work, extracts of Ageratina petiolaris, Bromelia karatas, Equisetum myriochaetum, Rhizophora mangle, and Smilax moranensis, which are Mexican plants that have been traditionally used to treat T2D, were assayed to evaluate their possible hepatic glucose output (HGO) inhibitory activity with a pyruvate tolerance test in 18-h fasted STZ-NA Wistar rats after oral administration of the extracts. In addition, the in vitro effects of the extracts on the last HGO rate-limiting enzyme G6Pase was analyzed. Our results showed that four of these plants had an effect on hepatic glucose production in the in vivo or in vitro assays. A. petiolaris and R. mangle extracts decreased glucose output, preventing an increase in the blood glucose levels and sustaining this prevented increase after pyruvate administration. Moreover, both extracts inhibited the catalytic activity of the G6Pase complex. On the other hand, even though S. moranensis and B. karatas did not exhibit a significant in vivo effect, S. moranensis had the most potent inhibitory effect on this enzymatic system, while the E. myriochaetum extract only inhibited hepatic glucose production in the pyruvate tolerance test. Because of the traditional method in which diabetic patients use plants, hepatic glucose production inhibition seems to be a mechanism that partially explains the common hypoglycemic effect. However, further studies must be carried out to characterize other mechanisms whereby these plants can decrease HGO.
format Online
Article
Text
id pubmed-7065531
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-70655312020-03-19 Hepatic Glucose Output Inhibition by Mexican Plants Used in the Treatment of Type 2 Diabetes Mata-Torres, Gerardo Andrade-Cetto, Adolfo Espinoza-Hernández, Fernanda Artemisa Cárdenas-Vázquez, René Front Pharmacol Pharmacology De novo hepatic glucose production or hepatic gluconeogenesis is the main contributor to hyperglycemia in the fasting state in patients with type 2 diabetes (T2D) owing to insulin resistance, which leads to at least twice as much glucose synthesis compared to healthy subjects. Therefore, control of this pathway is a promising target to avoid the chronic complications associated with elevated glucose levels. Patients with T2D in the rural communities of Mexico use medicinal plants prepared as infusions that are consumed over the day between meals, thus following this rationale (consumption of the infusions in the fasting state), one approach to understanding the possible mechanism of action of medicinal plants is to assess their capacity to inhibit hepatic glucose production. Furthermore, in several of these plants, the presence of phenolic acids able to block the enzyme glucose-6-phosphatase (G6Pase) is reported. In the present work, extracts of Ageratina petiolaris, Bromelia karatas, Equisetum myriochaetum, Rhizophora mangle, and Smilax moranensis, which are Mexican plants that have been traditionally used to treat T2D, were assayed to evaluate their possible hepatic glucose output (HGO) inhibitory activity with a pyruvate tolerance test in 18-h fasted STZ-NA Wistar rats after oral administration of the extracts. In addition, the in vitro effects of the extracts on the last HGO rate-limiting enzyme G6Pase was analyzed. Our results showed that four of these plants had an effect on hepatic glucose production in the in vivo or in vitro assays. A. petiolaris and R. mangle extracts decreased glucose output, preventing an increase in the blood glucose levels and sustaining this prevented increase after pyruvate administration. Moreover, both extracts inhibited the catalytic activity of the G6Pase complex. On the other hand, even though S. moranensis and B. karatas did not exhibit a significant in vivo effect, S. moranensis had the most potent inhibitory effect on this enzymatic system, while the E. myriochaetum extract only inhibited hepatic glucose production in the pyruvate tolerance test. Because of the traditional method in which diabetic patients use plants, hepatic glucose production inhibition seems to be a mechanism that partially explains the common hypoglycemic effect. However, further studies must be carried out to characterize other mechanisms whereby these plants can decrease HGO. Frontiers Media S.A. 2020-03-03 /pmc/articles/PMC7065531/ /pubmed/32194426 http://dx.doi.org/10.3389/fphar.2020.00215 Text en Copyright © 2020 Mata-Torres, Andrade-Cetto, Espinoza-Hernández and Cárdenas-Vázquez. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Pharmacology
Mata-Torres, Gerardo
Andrade-Cetto, Adolfo
Espinoza-Hernández, Fernanda Artemisa
Cárdenas-Vázquez, René
Hepatic Glucose Output Inhibition by Mexican Plants Used in the Treatment of Type 2 Diabetes
title Hepatic Glucose Output Inhibition by Mexican Plants Used in the Treatment of Type 2 Diabetes
title_full Hepatic Glucose Output Inhibition by Mexican Plants Used in the Treatment of Type 2 Diabetes
title_fullStr Hepatic Glucose Output Inhibition by Mexican Plants Used in the Treatment of Type 2 Diabetes
title_full_unstemmed Hepatic Glucose Output Inhibition by Mexican Plants Used in the Treatment of Type 2 Diabetes
title_short Hepatic Glucose Output Inhibition by Mexican Plants Used in the Treatment of Type 2 Diabetes
title_sort hepatic glucose output inhibition by mexican plants used in the treatment of type 2 diabetes
topic Pharmacology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7065531/
https://www.ncbi.nlm.nih.gov/pubmed/32194426
http://dx.doi.org/10.3389/fphar.2020.00215
work_keys_str_mv AT matatorresgerardo hepaticglucoseoutputinhibitionbymexicanplantsusedinthetreatmentoftype2diabetes
AT andradecettoadolfo hepaticglucoseoutputinhibitionbymexicanplantsusedinthetreatmentoftype2diabetes
AT espinozahernandezfernandaartemisa hepaticglucoseoutputinhibitionbymexicanplantsusedinthetreatmentoftype2diabetes
AT cardenasvazquezrene hepaticglucoseoutputinhibitionbymexicanplantsusedinthetreatmentoftype2diabetes